Loading…
Loading…
VIMGF does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for VIMGF and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for VIMGF and 80,000+ other tickers.
See exactly how VIMGF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for VIMGF and 80,000+ other tickers.
Vimian Group AB (publ) is an international enterprise focused on the animal health sector, organized into four distinct divisions: Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. The company offers a range of proprietary diagnostic tools and treatments under its Nextmune brand, providing both prescription and non-prescription options for the preventive care and management of chronic conditions in companion animals. Through its Indical Bioscience brand, Vimian delivers sophisticated molecular and immunodiagnostic solutions for laboratories, specifically targeting veterinary…
Vimian Group AB (publ) (VIMGF) Q2 2026 Earnings Call Transcript
Vimian Group AB (publ) (VIMGF) Q1 2026 Earnings Call Transcript
Vimian Group AB (publ) (VIMGF) Q4 2025 Earnings Call Transcript